Effects of Selenium supplementation on outcome of adult Hashimoto's thyroiditis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029407

Enrollment

Unknown

Registered

2020-01-30

Start date

2020-01-30

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

Euthyroid Hashimoto's thyroiditis:Selenium supplementation

subclinical hypothyroid patients:Selenium supplement

Healthy control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years old; 2. have lived in quanzhou for >= 5 years; 3. or patients without treatment in each of the euthyroid, subclinical hypothyroid patients.

Exclusion criteria

Exclusion criteria: 1. hyperthyreosis patients; 2. patients with overt hypothyroid; 3. pregnancy; 4. women preparing for pregnancy; 5. malignancy; 6. patients with acute or chronic infection; 7. history of connective tissue diseases; 8. exposure to drugs such as interferon, amiodarone, lipid lowering drugs or antioxidant vitamin supplementation.

Design outcomes

Primary

Measure	Time frame
blood Selenium;GSH-Px;SOD;TNF-a;	—

Secondary

Measure	Time frame
urine iodine;FT3;FT4;TSH;TGAb;TPOAb;thyroid volume;	—

Countries

China

Contacts

Public ContactZhou Jingxiong

The Second Hospital Affiliated to Fujian Medical University

zhoujx88@fjmu.edu.cn+86 18965501502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026